Information on EC 5.3.99.3 - prostaglandin-E synthase

New: Word Map on EC 5.3.99.3
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Bilateria

EC NUMBER
COMMENTARY
5.3.99.3
-
RECOMMENDED NAME
GeneOntology No.
prostaglandin-E synthase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
(13E)-(15S)-15-hydroxy-9-oxoprosta-10,13-dienoate = (13E)-(15S)-15-hydroxy-9-oxoprosta-11,13-dienoate
show the reaction diagram
-
-
-
-
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate = (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
catalytic mechanism of mPGES-2, hydrogen bond-forming residues Y107, C113, C110, and F112 are involved, substrate binding and catalytic sites
Q9N0A4
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
intramolecular oxidation
-
-
-
-
isomerization
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Arachidonic acid metabolism
-
-
arachidonic acid metabolism
-
-
C20 prostanoid biosynthesis
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
(5Z,13E)-(15S)-9alpha,11alpha-Epidioxy-15-hydroxyprosta-5,13-dienoate E-isomerase
Brings about the opening of the epidioxy bridge. Requires glutathione.
SYNONYMS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Endoperoxide isomerase
-
-
-
-
Isomerase, prostaglandin R2 E-
-
-
-
-
PGE isomerase
-
-
-
-
PGE2 isomerase
-
-
-
-
PGH-PGE isomerase
-
-
-
-
PGH2/PGE2 isomerase
-
-
-
-
prostagandin-E synthetase
-
-
-
-
Prostaglandin E synthase
-
-
-
-
Prostaglandin E2 isomerase
-
-
-
-
Prostaglandin endoperoxide E isomerase
-
-
-
-
Prostaglandin endoperoxide E2 isomerase
-
-
-
-
Prostaglandin endoperoxide-E isomerase
-
-
-
-
Prostaglandin H-E isomerase
-
-
-
-
Prostaglandin H-prostaglandin E isomerase
-
-
-
-
Prostaglandin R-prostaglandin E isomerase
-
-
-
-
Prostaglandin-H2 E-isomerase
-
-
-
-
CAS REGISTRY NUMBER
COMMENTARY
52227-79-9
-
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
zebrafish
SwissProt
Manually annotated by BRENDA team
inducible isozyme mPGES-1
-
-
Manually annotated by BRENDA team
isoform mPGES-1
-
-
Manually annotated by BRENDA team
isoform mPGES-2
-
-
Manually annotated by BRENDA team
isoform mPGES-2
SwissProt
Manually annotated by BRENDA team
isoforms mPGES-1 and cPGES
-
-
Manually annotated by BRENDA team
isoforms mPGES-1, mPGES-2 and cPGES
-
-
Manually annotated by BRENDA team
isozyme microsomal PGE2 synthase-1
SwissProt
Manually annotated by BRENDA team
microsomal isozyme mPGES-1
-
-
Manually annotated by BRENDA team
mPGES expression is induced by interleukin-1beta
-
-
Manually annotated by BRENDA team
women undergoing treatment for infertility, isozymes mPGES-2, mPGES-1, and cPGES
-
-
Manually annotated by BRENDA team
cPGES; cynomologus macaque, adult female, isozyme cPGES
SwissProt
Manually annotated by BRENDA team
isozyme mPGES2
SwissProt
Manually annotated by BRENDA team
mPGES-1; cynomologus macaque, adult female, isozyme mPGES-1
SwissProt
Manually annotated by BRENDA team
mPGES-2, truncated form; cynomologus macaque, adult female, isozyme mPGES-2
SwissProt
Manually annotated by BRENDA team
rhesus monkey
-
-
Manually annotated by BRENDA team
isoform mPGES-1
-
-
Manually annotated by BRENDA team
isozymes mPGES-2, mPGES-1, and cPGES
-
-
Manually annotated by BRENDA team
microsomal and cytosolic isoforms
UniProt
Manually annotated by BRENDA team
at least 2 different proteins with PGE-PGH isomerase activity: IgG1(hei-7)-reactive protein and IgG1(hei-26)-reactive protein
-
-
Manually annotated by BRENDA team
enzyme isoform mPGES1
-
-
Manually annotated by BRENDA team
adult female Sprague-Dawley rat
-
-
Manually annotated by BRENDA team
after induction of acid reflux oesophagitis. Expression of COX-2 and enzyme isoform mPGES-1 are markedly increased in oesophagitis and co-localize in epithelial cells of the basal layer, as well as inflammatory and mesenchymal cells in the lamina propria and submucosa
-
-
Manually annotated by BRENDA team
Sprague Dawley rat
-
-
Manually annotated by BRENDA team
Sprague-Dawley rat
-
-
Manually annotated by BRENDA team
Wistar rats
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
evolution
O14684
microsomal prostaglandin E2 synthase belongs to the MAPEG superfamily
evolution
-
the enzyme belongs to Sigma class glutathione transferase
malfunction
-
baseline blood pressures are significantly higher in mPGES1-deficientanimals than wild type controls
malfunction
-
mPGES-1-deficient mice exhibit significantly less neuronal loss induced by kainic acid
malfunction
-
small interfering RNA silencing of mPGES-1 in Lewis lung carcinoma cells decreases prostaglandin E2 synthesis markedly, accompanied by reduced cell proliferation, attenuated Matrigel invasiveness and increased extracellular matrix adhesion, while mPGES-1-overexpression shows increased proliferating and invasive capacities
malfunction
-
the deletion of mPGES-1 in mice results in increased prostacyclin I2 formation and marginal effects on the circulatory prostaglandin E2 level. Loss of mPGES-1 results in increased prostacyclin I2 formation, and in contrast to inhibition of prostacyclin I2, without worsening acute cardiac ischemic injury
malfunction
-
embryonic fibroblasts deficient in cPGES/p23 decrease the expression of the prostaglandin E2 degrading enzyme, 15-hydroxyprostaglandin dehydrogenase, which catalyzes the inactivating conversion of the PGE2 15-OH to a 15-keto group
malfunction
-
fibroblasts deficient in cPGES/p23 decrease the expression of the prostaglandin E2 degrading enzyme, 15-hydroxyprostaglandin dehydrogenase, which catalyzes the inactivating conversion of the PGE2 15-OH to a 15-keto group
malfunction
-
mPGES-1 knockdown delays tumor formation and reduced tumor weight in human cholangiocarcinoma tissue
malfunction
-
PGES-1-deficient mice exhibit reduced tumor growth in bone marrow and significantly fewer spontaneous flinches and their onset is several days later compared to wild type mice
malfunction
-
the expression of vascular endothelial growth factor A is significantly reduced in mPGES-1-deficient endometrial tissues implanted into mPGES-1-deficient mice at days 14 and 28
malfunction
-
the healing of acetic acid-induced gastric ulcers is significantly delayed in mPGES-1 knockout mice compared with wild type. This is accompanied with reduced angiogenesis in ulcer granulation tissues. The mRNA levels of proangiogenic growth factors, such as transforming growth factor-beta, basic fibroblast growth factor, and connective tissue growth factor are reduced in mPGES-1 knockout mice compared with wild type
metabolism
-
mPGES-1 is a rate-limiting enzyme that is coupled with cyclooxygenase-2 in the synthesis of prostaglandin E2
physiological function
-
microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are co-induced by excess glutamate in ischaemic brain. mPGES-1 activity is required for cyclooxygenase-2 to cause neuronal damage in ischaemic injury
physiological function
-
the enzyme is responsible for prostaglandin E2 synthesis in inflammation-associated pathologies
physiological function
-
microsomal prostaglandin E synthase-1 enhances bone cancer growth and bone cancer-related pain behaviors in mice
physiological function
-
mPGES-1 enhances the gastric ulcer-healing processes and the angiogenesis indispensable to gastric ulcer healing
physiological function
-
mPGES-1 regulates growth of endometrial tissues and angiogenesis
physiological function
-
overexpression of mPGES-1 in human cholangiocarcinoma cells increases tumor cell proliferation, migration, invasion, and colony formation. mPGES-1 inhibits the expression of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), leading to activation of the epidermal growth factor/phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathways in cholangiocarcinoma cells
metabolism
-
the prostaglandin E2-inactivating pathway is controlled by cPGES/p23
additional information
-
the electron-sharing network of the Bombyx mori enzyme includes Asn95, Asp96, and Arg98, the residues contribute to catalytic activity. The C-terminal domain contains the binding site for hydrophobic substrate and PGH2, active site and substrate binding site structures, overview
additional information
O14684
the isozyme mPGES-1 structure reveals three well-defined active site cavities within the membrane-spanning region in each monomer interface of the trimeric structure. An important determinant of the active site cavity is a small cytosolic domain inserted between transmembrane helices I and II. A a 16-A-deep cone-shaped cavity extending from the cytosolic side into the membrane-spanning region might have a potential role in substrate access. Serine 127 plays a role in the catalytic mechanism, active site structure, overview
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate + GSH
(5Z,13E)-(15S)-11a,15-dihydroxyprosta-5,13-dienoate + GSSG
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate + GSH
(5Z,13E)-(15S)-11a,15-dihydroxyprosta-5,13-dienoate + GSSG
show the reaction diagram
-
i.e. prostaglandin H2
i.e. prostaglandin E2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
Q9JM51
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
PGH2
PGE2
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + GSH
(5Z,13E)-(15S)-11alpha,15-dihydroxyprosta-5,13-dienoate + GSSG
show the reaction diagram
-
i.e. prostaglandin H2
i.e. prostaglandin E2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + GSH
(5Z,13E)-(15S)-11alpha,15-dihydroxyprosta-5,13-dienoate + GSSG
show the reaction diagram
O14684
i.e. prostaglandin H2
i.e. prostaglandin E2
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate + reduced glutathione
(5Z,13E)-(15S)-11alpha,15-dihydroxyprosta-5,13-dienoate + oxidized glutathione
show the reaction diagram
-
i.e. prostaglandin H2
i.e. prostaglandin E2
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
Q9N0A4
reaction of heme-free isozyme mPGES2
-
-
?
1-chloro-2,4-dinitrobenzene + GSH
?
show the reaction diagram
-
glutathione S-transferase activity
-
?
15-hydroperoxy-prostaglandin E2 + GSH
prostaglandin E2 + GSSG
show the reaction diagram
-
-
-
?
5-hydroperoxyeicosatetraenoic acid + 2 GSH
5-hydroxyeicosatetraenoic acid + GSSG + H2O
show the reaction diagram
-
-
-
?
Prostaglandin G1
15-Hydroperoxy-prostaglandin E1
show the reaction diagram
-
at 50% of the activity relative to prostaglandin H
major product
-
Prostaglandin G2
15-Hydroperoxy-prostaglandin E2
show the reaction diagram
-
at 50% of the activity relative to prostaglandin H
major product
-
Prostaglandin G2
15-Hydroperoxy-prostaglandin E2
show the reaction diagram
-
at pH 7.5, 2.5 mM glutathione and 10 microM substrate
-
-
?
prostaglandin G2 + GSH
15-hydroperoxy-prostaglandine E2 + GSSG
show the reaction diagram
-
-
-
?
Prostaglandin H
?
show the reaction diagram
-
involved in prostaglandin synthesis, which in the case of prostaglandin E is likely to be associated with the subversion or suppression of host immunity
-
-
-
Prostaglandin H1
Prostaglandin E1
show the reaction diagram
-
ir, i.e. 15-hydroxy-9alpha,11alpha-peroxidoprosta-13-enoic acid
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q3ZBF7, Q66LN0
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q9N0A4
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q95L14
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q5IHX6, Q5IHX7
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q6BCL2
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q5DI74, Q6PWL5, Q9N0A4
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
i.e. 15-hydroxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
i.e. 15-hydroxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
i.e. 15-hydroxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
i.e. 15-hydroxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
i.e. 15-hydroxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
i.e. 15-hydroxy-9alpha,11alpha-peroxidoprosta-5,13-dienoic acid
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
at pH 7.5, 2.5 mM glutathione and 10 microM substrate
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
isozyme mPEGS-2 has an important role in urogenital function
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
mPGES-1 is a gonadotropin-regulated enzyme
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q5DI74, Q6PWL5, Q9N0A4
mPGES-1 is a gonadotropin-regulated enzyme
-
-
?
cumene hydroperoxide + 2 GSH
cumene hydroxide + GSSG + H2O
show the reaction diagram
-
-
-
?
additional information
?
-
-
platelet-derived growth factor-induced increase in enzyme activity occurs within min after exposure to the growth factor
-
-
-
additional information
?
-
-
concordant induction of terminal prostaglandin E2 synthase with cyclooxygenase-2 leads to the preferred production of prostaglandin E2 over thromboxane B2 and prostaglandin D2, by lipopolysaccharide-stimulated macrophages
-
-
-
additional information
?
-
-
glutathione-heme-complex bound enzyme catalyzes formation of 12(S)-hydroxy-5(Z),8(E),10(E)-heptadecatrienoic acid and malonaldehyde from prostaglandin H2, i.e. shows lyase activity
-
-
-
additional information
?
-
Q9N0A4
heme-free isozyme mPGES2 and heme-bound isozyme mPGES2 catalyze isomerization of prostaglandin H2 to prostaglandin E2 and conversion of prostaglandin H2 to to (12S)-hydroxy-(5Z,8E,10E)-heptadecatrienoic acid and malondialdehyde, respectively
-
-
-
additional information
?
-
-
the enzyme also shows glutathione transferase activity with 1-chloro-2,4-dinitrobenzene
-
-
-
additional information
additional information
-
-
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate, PGH2, mutation R126A/Q creates a glutathione-dependent reductase which is able to convert prostaglandin H2 to prostaglandin F2alpha
(5Z,13E)-(15S)-9alpha,11alpha,15-trihydroxyprosta-5,13-dienoate, PGF2alpha
-
?
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
Q9JM51
-
-
-
?
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
PGH2
PGE2
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
-
-
-
-
?
Prostaglandin H
?
show the reaction diagram
-
involved in prostaglandin synthesis, which in the case of prostaglandin E is likely to be associated with the subversion or suppression of host immunity
-
-
-
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q9N0A4
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q5DI74, Q6PWL5, Q9N0A4
-
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
isozyme mPEGS-2 has an important role in urogenital function
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
-
mPGES-1 is a gonadotropin-regulated enzyme
-
-
?
Prostaglandin H2
Prostaglandin E2
show the reaction diagram
Q5DI74, Q6PWL5, Q9N0A4
mPGES-1 is a gonadotropin-regulated enzyme
-
-
?
(5Z,13E,15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
(5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate
show the reaction diagram
Q9N0A4
reaction of heme-free isozyme mPGES2
-
-
?
additional information
?
-
-
platelet-derived growth factor-induced increase in enzyme activity occurs within min after exposure to the growth factor
-
-
-
additional information
?
-
-
concordant induction of terminal prostaglandin E2 synthase with cyclooxygenase-2 leads to the preferred production of prostaglandin E2 over thromboxane B2 and prostaglandin D2, by lipopolysaccharide-stimulated macrophages
-
-
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
glutathione
-
-
glutathione
-
-
heme
-
crystallization data of red-coloured protein purified after growth of recombinant Escherichia coli in LB medium containing delta-aminolevulinate and Fe(NO3)3. Heme is complexed with bound glutathione forming a S-Fe coordination bond with no polar interaction with enzyme. Heme dissociation constant is 0.00053 mM
additional information
-
mutants R126A/Q possess glutathione-dependent reductase activity
-
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)acetic acid
-
35% inhibition at 0.001 mM
(2E)-2-(2,5-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]benzylidene)hexanoic acid
-
-
(2E)-2-(2,5-bis[[4-(trifluoromethyl)benzyl]oxy]benzylidene)hexanoic acid
-
55.1% residual activity at 0.01 mM
(2E)-2-[2,5-bis(2-cyclohexylethoxy)benzylidene]hexanoic acid
-
-
(2E)-2-[2,5-bis(2-phenylethoxy)benzylidene]hexanoic acid
-
-
(2E)-2-[2,5-bis(2-phenylethoxy)benzylidene]hexanoic acid}
-
-
-
(2E)-2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzylidene]hexanoic acid
-
28.3% residual activity at 0.01 mM
(2E)-2-[5-(2-cyclohexylethoxy)-2-[[4-(trifluoromethyl)benzyl]oxy]benzylidene]hexanoic acid
-
74% residual activity at 0.01 mM
(2R)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
(2S)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
(4-dodecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)acetic acid
-
22% inhibition at 0.001 mM
(4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)acetic acid
-
17% inhibition at 0.001 mM
(4E)-4-[2-(3-bromophenyl)hydrazin-1-ylidene]-1-ethanethioyl-3-methyl-4,5-dihydro-1H-pyrazol-5-one
-
-
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(5,8-dihydronaphthalen-1-yl)acetic acid
-
-
([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)acetic acid
-
75.4% residual activity at 0.01 mM
1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid
-
65% inhibition at 0.001 mM
1-[2-(2-methylphenyl)ethyl]-4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazole
-
90% residual activity at 0.03 mM
1-[4-[2-(2-carboxy-2-methylpropyl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-4-yl]-2-fluorophenyl]pyridinium
-
-
15-deoxy-DELTA12,14-prostaglandin J2
-
-
2(4-(3-biphenyloxypropoxy)phenylthio)hexanoic acid
-
-
2-(2,3-diphenethoxybenzylidene)hexanoic acid
-
-
2-(2-chloro-6-fluorophenyl)-4-(4-chlorophenyl)-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-(4-phenoxyphenyl)-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(2-phenylethyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylethynyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfonyl)phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-4-[4-[(E)-2-phenylethenyl]phenyl]-1H-imidazole
-
-
2-(2-chloro-6-fluorophenyl)-9-fluoro-3,6-dihydro-7H-benzo[h]imidazo[4,5-f]isoquinolin-7-one
-
-
2-(3,5-diphenethoxybenzyl)hexanoic acid
-
-
2-(3,5-diphenethoxybenzylidene)hexanoic acid
-
-
2-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
2-(4-dodecanoyl-3,5-dimethyl-1-phenylpyrrol-2-yl)acetic acid
-
23% inhibition at 0.001 mM
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
-
-
2-([4,6-bis[2-(4-cyanophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(4-methoxyphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
63.7% residual activity at 0.01 mM
2-([4,6-bis[2-(4-methylphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(4-nitrophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4,6-bis[2-(thiophen-3-yl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
-
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-chloro-6-[(4'-cyanobiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-chloro-6-[(5-methoxy-2-methylbiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-[(biphenyl-4-ylmethyl)amino]-6-chloropyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
88.3% residual activity at 0.01 mM
2-([4-[3-(2-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(3-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
59.1% residual activity at 0.01 mM
2-([4-[3-(3-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
58% residual activity at 0.01 mM
2-([4-[3-(4-chloro-2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(4-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
-
2-chloro-N-[3-(naphthalen-1-ylcarbamoyl)phenyl]benzamide
-
selective for human over rat MPGES1
2-chloro-N-[3-(naphthalen-1-ylcarbamoyl)phenyl]benzamide
-
inhibitor of mutant enzyme V131T/F135L/F138A, but not of the wild type enzyme
2-[(3,5-diphenethoxyphenyl)thio]hexanoic acid
-
-
2-[(4,6-bis[2-[4-(trifluoromethoxy)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
-
88.3% residual activity at 0.01 mM
2-[(4,6-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
-
-
2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid
-
-
2-[(4-[3-[2-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[3-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[3-[4-chloro-3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
-
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]nonanoic acid
-
-
2-[2,3-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[2,4-bis(2-phenylethoxy)benzyl]hexanoic acid
-
90.1% residual activity at 0.01 mM
2-[2,5-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[2,5-bis(2-phenylethoxy)benzyl]hexanoic acid}
-
-
-
2-[2-(2-chloro-6-fluorophenyl)-4-[6-(phenylethynyl)pyridin-3-yl]-1H-imidazol-5-yl]ethanol
-
-
2-[3,4-bis(2-phenylethoxy)benzyl]hexanoic acid
-
-
2-[3,5-bis(2-phenylethoxy)phenoxy]hexanoic acid
-
-
2-[3-(aminooxy)-2,2-dimethyl-3-oxopropyl]-3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indole
-
IC50: 0.01 mM
2-[4-(4-bromophenyl)-1H-imidazol-2-yl]benzonitrile
-
-
2-[4-(4-chlorophenyl)-1H-imidazol-2-yl]-3-fluorobenzonitrile
-
-
2-[4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)phenyl]propan-2-ol
-
-
2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzyl]hexanoic acid
-
-
2-[6-(2-cyclopropylethoxy)-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid
-
licofelone, ML3000
2-[6-bromo-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-chloro-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[6-chloro-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
2-[[4,6-bis(2-cycloheptylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
62.4% residual activity at 0.01 mM
2-[[4,6-bis(2-cyclohexylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(2-cyclopentylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
90% residual activity at 0.01 mM
2-[[4,6-bis(2-cyclopropylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]butanoic acid
-
-
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]butanoic acid}
-
-
-
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]octanoic acid
-
-
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]octanoic acid}
-
-
-
2-[[4,6-bis(3-methylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
54.5% residual activity at 0.01 mM
2-[[4,6-bis(3-phenylpropoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(4-phenylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4,6-bis(benzyloxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
-
2-[[4-(3-phenoxypropoxy)phenyl]sulfanyl]hexanoic acid
-
81.9% residual activity at 0.01 mM
2-[[4-(biphenyl-4-ylamino)-6-chloropyrimidin-2-yl]sulfanyl]nonanoic acid
-
-
3,4-bis-(3-benzo[b]thiophen-3-yl-phenyl)-5-hydroxy-5H-furan-2-one
Q9JM51
-
3-(1,3,5-trimethyl-4-octadecanoyl-1H-pyrrol-2-yl)propanoic acid
-
97% inhibition at 0.001 mM
3-(1,3,5-trimethyl-4-tetradecanoyl-1H-pyrrol-2-yl)propanoic acid
-
91% inhibition at 0.001 mM
3-(1-benzothiophen-2-yl)-2-bromo-5-hydroxycyclopent-2-en-1-one
-
-
3-(1-benzyl-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)propanoic acid
-
62% inhibition at 0.001 mM
3-(1-benzyl-4-dodecanoyl-5-methyl-3-phenylpyrrol-2-yl)propionic acid
-
64% inhibition at 0.001 mM
3-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazole
-
-
3-(4-dodecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid
-
54% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)-N-(benzenesulfonyl)propanamide
-
77% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)-N-(methanesulfonyl)propanamide
-
52% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanamide
-
39% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanehydrazide
-
35% inhibition at 0.001 mM
3-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)propanenitrile
-
22% inhibition at 0.001 mM
3-(4-dodecanoyl-1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)propanoic acid
-
90% inhibition at 0.001 mM
3-(4-dodecanoyl-3,5-dimethyl-1-phenylpyrrol-2-yl)propionic acid
-
65% inhibition at 0.001 mM
3-(4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl)propanoic acid
-
38% inhibition at 0.001 mM
3-(4-hexadecanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid
-
97% inhibition at 0.001 mM
3-(naphthalen-1-ylamino)-6-nitrobenzo[d]isothiazole 1,1-dioxide
-
-
3-benzamidocarbazole
-
-
3-bromo-4-(4'-butyl-biphenyl-4-yl)-5-hydroxy-5H-furan-2-one
Q9JM51
-
3-bromo-5-hydroxy-4-[1,1':4',1'']terphenyl-4-yl-5H-furan-2-one
Q9JM51
-
3-[(5E)-3-(4-butylbenzyl)-1-(4-chlorobenzyl)-4-methylidene-5-[(2E)-4-methylpent-2-en-1-ylidene]-4,5-dihydro-1H-pyrrol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00029 mM
3-[1-(4-carbamoylbenzyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
28% inhibition at 0.001 mM
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00025 mM
3-[1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0032 mM
3-[1-(4-chlorobenzyl)-3-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0011 mM
3-[1-(4-chlorobenzyl)-3-methyl-5-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00060 mM
3-[1-(4-chlorobenzyl)-3-methyl-7-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0043 mM
3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid
-
MK-886
3-[1-(4-chlorobenzyl)-4-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
78% inhibition at 0.001 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenoxy-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00065 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0064 mM
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-[(2-methylphenyl)carbonyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00090 mM
3-[1-(4-chlorobenzyl)-5-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000004 mM
3-[1-(4-chlorobenzyl)-5-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000008 mM
3-[1-(4-chlorobenzyl)-5-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000022 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000005 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000003 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-3'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000033 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-4'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000031 mM
3-[1-(4-chlorobenzyl)-5-(2-fluoro-5-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000007 mM
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[1-(4-chlorobenzyl)-5-(3-fluoro-4-pyridin-3-ylphenyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000012 mM
3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0026 mM
3-[1-(4-chlorobenzyl)-5-[2-fluoro-2'-(phenylcarbonyl)biphenyl-4-yl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000006 mM
3-[1-(4-chlorobenzyl)-5-[3-fluoro-4-(pyrimidin-5-ylmethyl)phenyl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000032 mM
3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid
-
i.e. 3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid or FLAP, formerly designated L-663,536, a lipoxygenase inhibitor, IC50: 0.0016 mM
3-[3-(benzylsulfanyl)-1-(4-chlorobenzyl)-5-[4-[(4-chloro-2-fluorophenyl)ethynyl]phenyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
12% residual activity at 0.03 mM
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
75% inhibition at 0.01 mM
3-[3-(tert-butylsulfanyl)-1-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.01 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-(3-phenylpropyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0032 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-prop-2-en-1-yl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0067 mM
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.01 mM
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00026 mM
3-[4-(2'-acetyl-2-fluorobiphenyl-4-yl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[4-(4-butoxybenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid
-
32% inhibition at 0.001 mM
3-[4-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
3-[4-dodecanoyl-1-(4-hydroxybenzyl)-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
53% inhibition at 0.001 mM
3-[4-dodecanoyl-1-(4-methoxybenzyl)-3,5-dimethyl-1H-pyrrol-2-yl]propanoic acid
-
72% inhibition at 0.001 mM
3-[4-dodecanoyl-3,5-dimethyl-1-(4-methylbenzyl)-1H-pyrrol-2-yl]propanoic acid
-
52% inhibition at 0.001 mM
3-[4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]propanoic acid
-
83.9% residual activity at 0.01 mM
3-[5-biphenyl-3-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00016 mM
3-[5-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000016 mM
3-[5-tert-butyl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00033 mM
4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
-
73.6% residual activity at 0.03 mM
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-3-ol
-
60.1% residual activity at 0.03 mM
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
-
89% residual activity at 0.03 mM
4'-[1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-amine
-
98.2% residual activity at 0.03 mM
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
91.9% residual activity at 0.03 mM
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazole
-
87.9% residual activity at 0.03 mM
4-(4'-butyl-biphenyl-4-yl)-3-(4-butyl-phenyl)-5-hydroxy-5H-furan-2-one
Q9JM51
-
4-(4'-phenoxybiphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
88.7% residual activity at 0.03 mM
4-(4-benzylphenyl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
4-(4-chlorobenzyl)-2,6-bis[4-(trifluoromethoxy)phenyl]-4H-thieno[3,2-b]pyrrole
-
-
4-(4-dodecanoyl-1,3,5-trimethylpyrrol-2-yl)butanoic acid
-
70% inhibition at 0.001 mM
4-(biphenyl-4-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
-
-
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzamide
-
-
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzoic acid
-
-
4-dodecanoyl-1,3,5-trimethyl-1H-pyrrole-2-carboxylic acid
-
37% inhibition at 0.001 mM; 59% inhibition at 0.001 mM
4-dodecanoyl-3,5-dimethyl-1-phenylpyrrole-2-carboxylic acid
-
99% inhibition at 0.001 mM
4-dodecanoyl-3,5-dimethyl-1H-pyrrole-2-carboxylic acid
-
62% inhibition at 0.001 mM
4-[(4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazol-1-yl)sulfonyl]benzoic acid
-
59.8% residual activity at 0.03 mM
4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
96.8% residual activity at 0.03 mM
4-[4-(phenanthren-9-yl)phenyl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
78.2% residual activity at 0.03 mM
4-[4-benzyl-1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-5-yl]benzaldehyde
-
72.1% residual activity at 0.03 mM
4-[[2-(2-carboxyethyl)-4-dodecanoyl-3,5-dimethyl-1H-pyrrol-1-yl]methyl]benzoic acid
-
27% inhibition at 0.001 mM
4-[[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]methyl]-3-nitrobenzoic acid
-
most efficient inhibitor of mPGES-1, 12% residual activity at 0.03 mM
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
-
-
5-(4-bromophenyl)-3-(2-chloro-6-fluorophenyl)-1,2,4-oxadiazole
-
-
5-(4-cyclohexylphenyl)-1-[4-(1-methylethoxy)benzyl]-1H-indole-2-carboxylic acid
-
-
5-(4-tert-butylphenyl)-1-[4-(1-methylethoxy)benzyl]-1H-indole-2-carboxylic acid
-
-
5-(4-tert-butylphenyl)-3-[4-(1-methylethoxy)phenyl]-1-[4-[(1-methylethyl)amino]benzyl]-1H-indole-2-carboxylic acid
-
-
5-(dimethylamino)-N-[4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-yl]naphthalene-1-sulfonamide
-
85% residual activity at 0.03 mM
5-hydroxy-3-naphthalen-2-yl-4-(3-naphthalen-2-yl-phenyl)-5H-furan-2-one
Q9JM51
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(1,3-thiazol-2-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohex-1-en-1-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohexylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclopropylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(pyridin-3-ylethynyl)pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-ethynylpyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(2-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(3-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(4-chlorophenyl)ethynyl]pyridine
-
-
5-[2-(2-chloro-6-fluorophenyl)-5-methyl-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-bromo-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
5-[5-chloro-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
-
6-nitro-3-(m-tolylamino) benzo[d]isothiazole 1,1-dioxide
-
i.e. JMC-7
6-nitro-N-phenyl-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
6-nitro-N-[3-(propan-2-yl)phenyl]-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
7-hydroxy-N,N'-bis(2,4,6-trimethylphenyl)naphthalene-1,3-disulfonamide
-
-
acetaminophen
-
-
aminomethyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
-
-
arachidonic acid
-
-
benzothiophene gamma-hydroxybutenolide
Q9JM51
-
biarylimidazole
-
-
Bis(3-carboxy-4-nitrophenyl)disulfide
-
-
cysteinyl leukotriene LTC4
-
-
deoxy-prostaglandin J2
-
IC50: 0.0003 mM
dexamethasone
-
anti-inflammatory glucocorticoid
dexamethasone
-
inhibition of cytokine-induced expression of isoform mPGES-1, while isoforms mPGES-2 and cPGES remain unaffected
Diallyl disulfide-oxide
-
i.e. allicin
dyphylline
-
-
eicosapentaenoic acid
-
-
ethyl 2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
-
ethyl 2-([4-[3-(biphenyl-4-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
-
ethyl 2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
83.9% residual activity at 0.01 mM
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]nonanoate
-
-
geldanamycin
-
-
heme
Q9N0A4
heme is bound to the enzyme subunits and alters the enzyme catalytic specificity, overview. Heme is attached to the bound GSH by an iron-sulfur bond, but heme cannot bind to mPGES2 in the absence of GSH, other sulfhydryl compounds, such as DTT and 2-mercaptoethanol, are unable to promote heme binding to isozyme mPGES2. Bound heme is oxidized by H2O2, but it does not dissociate from mPGES2
HgCl2
-
-
imidazole
Q9N0A4
imidazole stacks on the bound heme and inhibits heme oxidation by H2O2, heme dissociation by DTT, and catalytic activity
Indocyanine green
-
-
iodoacetamide
-
-
iodoacetic acid
-
-
Iodosobenzoic acid
-
-
leukotriene C4
-
-
methyl 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoate
-
IC50: 0.0072 mM
methyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
-
-
methyl 4-[6-bromo-2-(2-chloro-6-fluorophenyl)-1H-phenanthro[9,10-d]imidazol-9-yl]but-3-ynoate
-
-
MK 886
-
inhibits microsomal PGE2
MK-0886
-
0.002 mM, 50% inhibition
MK-886
-
inhibition of cytokine-induced expression of isoform mPGES-1, while isoforms mPGES-2 and cPGES remain unaffected
MK-886
-
glutamate-induced PGE2 production is suppressed almost completely by MK-886 at a concentration of 0.003 mM or higher
MK-886
-
i.e. 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid
N-(1,3-benzodioxol-4-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(2-methylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3,4-dimethoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-bromobenzyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-bromophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-chlorophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(3-tert-butylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(4-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(5-bromonaphthalen-1-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-(6-nitro-1,1-dioxido-1,2-benzothiazol-3-yl)quinolin-5-amine
-
-
N-(biphenyl-3-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
-
N-[4-chloro-3-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-2-(trifluoromethyl)benzamide
-
-
NEM
-
-
NEM
-
-
NS-398
-
COX-2 inhibitor, IC50: 0.01-0.02 mM
Oxacillin
-
-
p-hydroxymercuribenzoate
-
-
PCMB
-
-
PF-9184
-
potent, competitive and reversible mPGES-1 inhibitor, i.e. N-(3',4'-dichlorobiphenyl-4-yl)-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
PF-9184
-
poor mPGES-1 inhibitor, i.e. N-(3',4'-dichlorobiphenyl-4-yl)-4-hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
resveratrol
-
-
SB-203580
-
blocks the association of cPGES with casein kinase II and Hsp90, as well as cPGES phosphorylation
sulindac
-
-
sulindac sulfide
-
-
[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]methyl benzoate
-
76.1% residual activity at 0.03 mM
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl](phenyl)acetic acid
-
-
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]acetic acid
-
66.4% residual activity at 0.01 mM
MK886
-
-
additional information
-
anti-inflammatory glucocorticoids
-
additional information
-
glucocorticosteroids, down-regulation of the enzyme
-
additional information
-
structure-activity relationship analysis of inhibitors
-
additional information
-
not inhibited by BWA4C, i.e. (E)-N-hydroxy-N-(3-(3-phenoxyphenyl)-allyl)acetamide
-
additional information
-
synthesis and inhibitory potency of a series of 6-nitro-3-(m-tolylamino) benzo[d]isothiazole 1,1-dioxide analogues against microsomal prostaglandin E2 synthase. No inhibition by Zileuton
-
additional information
-
pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1, overview. No inhibition at 0.001 mM by 3-(4-butanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, 3-(4-heptanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, 3-(1,3,5-trimethyl-4-octanoyl-1H-pyrrol-2-yl)propanoic acid, 3-(4-decanoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, 3-[1,3,5-trimethyl-4-[2-(octyloxy)benzoyl]-1H-pyrrol-2-yl]propanoic acid, 3-[4-(3-heptyloxybenzoyl)-1,3,5-trimethylpyrrol-2-yl]propionic acid, 3-(4-benzoyl-1,3,5-trimethyl-1H-pyrrol-2-yl)propanoic acid, 3-[1,3,5-trimethyl-4-(naphthalen-1-ylcarbonyl)-1H-pyrrol-2-yl]propanoic acid, 3-[1,3,5-trimethyl-4-(naphthalen-2-ylcarbonyl)-1H-pyrrol-2-yl]propanoic acid, 3-[4-(2-ethylbenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid, 3-[4-(4-ethylbenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid, 3-[4-(4-benzylbenzoyl)-1,3,5-trimethyl-1H-pyrrol-2-yl]propanoic acid, 4-dodecanoyl-1-methyl-1H-pyrrole-2-carboxylic acid, (4-dodecanoyl-1-methyl-1H-pyrrol-2-yl)acetic acid, and 3-(4-dodecanoyl-1-methyl-1H-pyrrol-2-yl)propanoic acid
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
17beta-estradiol
-
up-regulates PTGES mRNA and protein level
all-trans retinoic acid
-
ATRA
angiotension II
-
angiotension II infusion induces mRNA expression of mPGES-1, mPGES-2 and cytosolic PGE synthase
-
bradykinin
-
-
captoprylsulfobetaine
-
10 mM, 2.6fold activation
diheptanoylphosphatidylcholine
-
2.2 mM, 4.8fold activation
Dihydrolipoic acid
-
-
dithiothreitol
-
-
dithiothreitol
Q9N0A4
leads to dissociation of the bound heme which is hindered by imidazole
epigallocatechin gallate
-
enhances COX-2 and isoform mPGES-1 gene expression and production of prostaglandin E2. Induction of mPGES-1 is mediated by active ERK1/2MAP kinases and early growth response gene 1
glutathione
-
-
glutathione
-
-
glutathione
-
-
glutathione
-
-
glutathione
-
the N-terminal domain contains the GSH-binding site (G-site)
GSH
-
2 mM required for maximal activity of IgG1(hei-7)-reactive protein; concentrations below 0.5 mM are required for maximal activity of IgG1(hei-26)-reactive protein; dependent on
GSH
-
dependent on
GSH
-
dependent on
GSH
-
two different types of prostaglandin E synthase: 1. GSH-dependent enzyme, 2. GSH-independent enzyme. The genitally organs, especially the deferent duct have mainly GSH-dependent prostaglandin E synthase activity. Heart, spleen and uterus have only the GSH-independent activity. In absence of reduced glutathione the enzyme from deferent duct shows only 3% of the activity in presence of reduced glutathione
GSH
Q9N0A4
mPGES2 has a GSH-binding motif, the GSH molecule binds at the predicted amino acid residues 148VPxL to 164DSxxI. GSH is essential for heme binding to isozyme mPGES2, structures of GSH-heme complex-binding cavity in isozyme mPGES2, overview
Hsp90
-
maximal activity is achieved when the three components (cPGES, casein kinase II and Hsp90) are mixed at a molar proportion of 1:1:1
-
interleukin 1beta
-
increase in protein expression and activity of isoform mPGES-1, accompanied by increased COX-2 expression and production of prostaglandin E2
-
interleukin 1beta
-
induces isoform mPGES-1 and subsequent production of prostaglandin E2, while production of prostaglandin I2 is reduced by increased expression of mPGES-1
-
interleukin 1beta
-
stimulates release of prostaglandin E2 by myometrical smooth muscle cells and increases COX-2 and mPGES-1 mRNA and protein expression
-
Interleukin-1beta
-
-
-
lipopolysaccharide
-
lipopolysaccharide binds to receptor TLR4 on osteoblasts that directly induces isoform mPGES-1 expression for prostaglandin E2 synthesis, leading to subsequent bone resorption
n-dodecylmaltoside
-
0.3 mM, 5fold activation
n-octylglucoside
-
34 mM, 3.3fold activation
thiol reagents
-
-
TNF-alpha
-
-
-
TNF-beta
-
-
-
TNFalpha
-
-
-
Triton X-100
-
5 mM, 4.6fold activation
Tumor necrosis factor alpha
-
increase in protein expression and activity of isoform mPGES-1, accompanied by increased COX-2 expression and production of prostaglandin E2
-
LPS
-
-
-
additional information
-
phosphorylation is crucial for the enzyme's function, phosphorylation by casein kinase II enhances cPGES activity 3fold
-
additional information
-
IL-1 administration into the mouse cortex leads to elevated expression of cPGES and an increase in prostaglandin E2
-
additional information
-
proinflammatory stimuli
-
additional information
-
proinflammatory cytokinin, induction of the enzyme
-
additional information
-
lipopolysaccharide significantly increases the mRNA level of mPGES-1
-
additional information
-
mPGES-1 expression is upregulated in COX-1 and COX-2 knock-out cells
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.13
(5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate
-
wild-type, 0C, pH 7.2
0.734
(5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate
-
mutant Q134E, 0C, pH 7.2
1.61
(5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate
-
mutant Q36E, 0C, pH 7.2
0.0024
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
-
0.014
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
-
0.1
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
in the presence of 0.3 mM dodecylmaltoside
0.16
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
-
0.6
glutathione
-
in the presence of 0.3 mM dodecylmaltoside
0.71
glutathione
-
-
0.75
glutathione
-
-
0.05
Prostaglandin G1
-
-
0.16
prostaglandin G2
-
-
0.01
Prostaglandin H1
-
-
0.0149
prostaglandin H2
-
cPGES plus casein kinase II plus Hsp90
0.0257
prostaglandin H2
-
GSH-dependent enzyme from deferent duct
0.0357
prostaglandin H2
-
cPGES plus casein kinase II
0.04
prostaglandin H2
-
IgG1(hei-7)-reactive protein
0.0666
prostaglandin H2
-
cPGES alone
0.0826
prostaglandin H2
-
GSH-independent enzyme from heart
0.15
prostaglandin H2
-
IgG1(hei-26)-reactive protein
0.16
prostaglandin H2
-
-
0.215
prostaglandin H2
-
wild type enzyme
0.2832
prostaglandin H2
-
mutant enzyme Y117S
0.296
prostaglandin H2
-
mutant enzyme R70A
0.372
prostaglandin H2
-
mutant enzyme R122A
0.3842
prostaglandin H2
-
mutant enzyme T129V
0.4643
prostaglandin H2
-
mutant enzyme N74A
0.4737
prostaglandin H2
-
mutant enzyme R70A/R122A
0.5345
prostaglandin H2
-
mutant enzyme Y117A
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
7
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
dodecylmaltoside activated
50
(5Z,13E)-(15S)-9alpha,11alpha-epidioxy-15-hydroxyprosta-5,13-dienoate
-
-
21
glutathione
-
-
75
prostaglandin G2
-
-
50
prostaglandin H2
-
-
75
prostaglandine G2
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0035
(2E)-2-(2,5-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]benzylidene)hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
(2E)-2-(2,5-bis[[4-(trifluoromethyl)benzyl]oxy]benzylidene)hexanoic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0034
(2E)-2-[2,5-bis(2-cyclohexylethoxy)benzylidene]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0015
(2E)-2-[2,5-bis(2-phenylethoxy)benzylidene]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
(2E)-2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzylidene]hexanoic acid
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.01
(2E)-2-[5-(2-cyclohexylethoxy)-2-[[4-(trifluoromethyl)benzyl]oxy]benzylidene]hexanoic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0042
(2R)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0046
(2S)-2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0051
([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)(5,8-dihydronaphthalen-1-yl)acetic acid
-
-
0.01
([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)acetic acid
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.03
1-[2-(2-methylphenyl)ethyl]-4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazole
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.000012
1-[4-[2-(2-carboxy-2-methylpropyl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-4-yl]-2-fluorophenyl]pyridinium
-
-
0.0003
15-deoxy-DELTA12,14-prostaglandin J2
-
-
0.0022
2(4-(3-biphenyloxypropoxy)phenylthio)hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0011
2-(2,3-diphenethoxybenzylidene)hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.00066
2-(2-chloro-6-fluorophenyl)-4-(4-chlorophenyl)-1H-imidazole
-
pH and temperature not specified in the publication
0.00032
2-(2-chloro-6-fluorophenyl)-4-(4-phenoxyphenyl)-1H-imidazole
-
pH and temperature not specified in the publication
0.00015
2-(2-chloro-6-fluorophenyl)-4-[4-(2-phenylethyl)phenyl]-1H-imidazole
-
pH and temperature not specified in the publication
0.000008
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylethynyl)phenyl]-1H-imidazole
-
pH and temperature not specified in the publication
0.00018
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfanyl)phenyl]-1H-imidazole
-
pH and temperature not specified in the publication
0.0014
2-(2-chloro-6-fluorophenyl)-4-[4-(phenylsulfonyl)phenyl]-1H-imidazole
-
pH and temperature not specified in the publication
0.000035
2-(2-chloro-6-fluorophenyl)-4-[4-[(E)-2-phenylethenyl]phenyl]-1H-imidazole
-
pH and temperature not specified in the publication
0.0024
2-(3,5-diphenethoxybenzyl)hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0028
2-(3,5-diphenethoxybenzylidene)hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0037
2-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-imidazole
-
pH and temperature not specified in the publication
0.000001
2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)benzene-1,3-dicarbonitrile
-
-
0.0059
2-([4,6-bis[2-(4-cyanophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-([4,6-bis[2-(4-methoxyphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0009
2-([4,6-bis[2-(4-methylphenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0037
2-([4,6-bis[2-(4-nitrophenyl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0065
2-([4,6-bis[2-(thiophen-3-yl)ethoxy]pyrimidin-2-yl]sulfanyl)hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0039
2-([4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
0.0017
2-([4-chloro-6-[(4'-cyanobiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
0.0021
2-([4-chloro-6-[(5-methoxy-2-methylbiphenyl-4-yl)amino]pyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
0.0013
2-([4-[(biphenyl-4-ylmethyl)amino]-6-chloropyrimidin-2-yl]sulfanyl)nonanoic acid
-
-
0.0029
2-([4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.01
2-([4-[3-(2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0088
2-([4-[3-(2-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.01
2-([4-[3-(3-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.01
2-([4-[3-(3-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0094
2-([4-[3-(4-chloro-2-methoxyphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0093
2-([4-[3-(4-methylphenoxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0022
2-([4-[3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.01
2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoic acid
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.000058
2-chloro-N-[3-(naphthalen-1-ylcarbamoyl)phenyl]benzamide
-
wild type enzyme, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.00059
2-chloro-N-[3-(naphthalen-1-ylcarbamoyl)phenyl]benzamide
-
mutant enzyme V131T/F135L/F138A, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.0046
2-[(3,5-diphenethoxyphenyl)thio]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[(4,6-bis[2-[4-(trifluoromethoxy)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0019
2-[(4,6-bis[2-[4-(trifluoromethyl)phenyl]ethoxy]pyrimidin-2-yl)sulfanyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0012
2-[(4,6-diphenethoxypyrimidin-2-yl)thio]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0041
2-[(4-[3-[2-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0027
2-[(4-[3-[3-(propan-2-yl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.002
2-[(4-[3-[3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0017
2-[(4-[3-[4-chloro-3-(trifluoromethyl)phenoxy]propoxy]phenyl)sulfanyl]hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0026
2-[(4-[[3,5-bis(2,2,2-trifluoroethoxy)phenyl]amino]-6-chloropyrimidin-2-yl)sulfanyl]nonanoic acid
-
-
0.0039
2-[2,3-bis(2-phenylethoxy)benzyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[2,4-bis(2-phenylethoxy)benzyl]hexanoic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0024
2-[2,5-bis(2-phenylethoxy)benzyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.00018
2-[2-(2-chloro-6-fluorophenyl)-4-[6-(phenylethynyl)pyridin-3-yl]-1H-imidazol-5-yl]ethanol
-
pH and temperature not specified in the publication
0.0027
2-[3,4-bis(2-phenylethoxy)benzyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0006
2-[3,5-bis(2-phenylethoxy)phenoxy]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[3-(aminooxy)-2,2-dimethyl-3-oxopropyl]-3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indole
-
IC50: 0.01 mM
0.0014
2-[4-(4-bromophenyl)-1H-imidazol-2-yl]benzonitrile
-
pH and temperature not specified in the publication
0.001
2-[4-(4-chlorophenyl)-1H-imidazol-2-yl]-3-fluorobenzonitrile
-
pH and temperature not specified in the publication
0.005
2-[4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)phenyl]propan-2-ol
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0071
2-[4-[3-(2,3-dimethylphenoxy)propoxy]benzyl]hexanoic acid
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0000009
2-[6-(2-cyclopropylethoxy)-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
0.006
2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid
-
-
0.0000009
2-[6-bromo-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
0.0000009
2-[6-chloro-9-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
0.0000007
2-[6-chloro-9-(3-hydroxy-3-methylbutyl)-1H-phenanthro[9,10-d]imidazol-2-yl]benzene-1,3-dicarbonitrile
-
-
0.01
2-[[4,6-bis(2-cycloheptylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0024
2-[[4,6-bis(2-cyclohexylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[[4,6-bis(2-cyclopentylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0096
2-[[4,6-bis(2-cyclopropylethoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0073
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]butanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.002
2-[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]octanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[[4,6-bis(3-methylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0022
2-[[4,6-bis(3-phenylpropoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0009
2-[[4,6-bis(4-phenylbutoxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0038
2-[[4,6-bis(benzyloxy)pyrimidin-2-yl]sulfanyl]hexanoic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
2-[[4-(3-phenoxypropoxy)phenyl]sulfanyl]hexanoic acid
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0016
2-[[4-(biphenyl-4-ylamino)-6-chloropyrimidin-2-yl]sulfanyl]nonanoic acid
-
-
0.00323
3,4-bis-(3-benzo[b]thiophen-3-yl-phenyl)-5-hydroxy-5H-furan-2-one
Q9JM51
-
0.0018
3-(1-benzothiophen-2-yl)-2-bromo-5-hydroxycyclopent-2-en-1-one
-
-
0.00011
3-(4-bromophenyl)-5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazole
-
pH and temperature not specified in the publication
0.0021
3-(naphthalen-1-ylamino)-6-nitrobenzo[d]isothiazole 1,1-dioxide
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.002
3-benzamidocarbazole
-
-
0.00224
3-bromo-4-(4'-butyl-biphenyl-4-yl)-5-hydroxy-5H-furan-2-one
Q9JM51
-
0.00361
3-bromo-5-hydroxy-4-[1,1':4',1'']terphenyl-4-yl-5H-furan-2-one
Q9JM51
-
0.00029
3-[(5E)-3-(4-butylbenzyl)-1-(4-chlorobenzyl)-4-methylidene-5-[(2E)-4-methylpent-2-en-1-ylidene]-4,5-dihydro-1H-pyrrol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00029 mM
0.00025
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.00025
3-[1-(4-chlorobenzyl)-3-(3,3-dimethylbutanoyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00025 mM
0.0032
3-[1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0032 mM
0.0011
3-[1-(4-chlorobenzyl)-3-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0011 mM
0.0006
3-[1-(4-chlorobenzyl)-3-methyl-5-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00060 mM
0.0043
3-[1-(4-chlorobenzyl)-3-methyl-7-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0043 mM
0.002
3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.000004
3-[1-(4-chlorobenzyl)-4-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.000008
3-[1-(4-chlorobenzyl)-4-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.000022
3-[1-(4-chlorobenzyl)-4-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.000005
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.000003
3-[1-(4-chlorobenzyl)-4-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.000007
3-[1-(4-chlorobenzyl)-4-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.00065
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenoxy-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00065 mM
0.0064
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-phenyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0064 mM
0.0009
3-[1-(4-chlorobenzyl)-5-(1-methylethyl)-3-[(2-methylphenyl)carbonyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00090 mM
0.000004
3-[1-(4-chlorobenzyl)-5-(2'-chloro-2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000004 mM
0.000008
3-[1-(4-chlorobenzyl)-5-(2,2'-difluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000008 mM
0.000022
3-[1-(4-chlorobenzyl)-5-(2-chlorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000022 mM
0.000005
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methoxybiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000005 mM
0.000003
3-[1-(4-chlorobenzyl)-5-(2-fluoro-2'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000003 mM
0.000033
3-[1-(4-chlorobenzyl)-5-(2-fluoro-3'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000033 mM
0.000031
3-[1-(4-chlorobenzyl)-5-(2-fluoro-4'-methylbiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000031 mM
0.000007
3-[1-(4-chlorobenzyl)-5-(2-fluorobiphenyl-4-yl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000007 mM
0.000012
3-[1-(4-chlorobenzyl)-5-(3-fluoro-4-pyridin-3-ylphenyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000012 mM
0.0026
3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0026 mM
0.000006
3-[1-(4-chlorobenzyl)-5-[2-fluoro-2'-(phenylcarbonyl)biphenyl-4-yl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000006 mM
0.000032
3-[1-(4-chlorobenzyl)-5-[3-fluoro-4-(pyrimidin-5-ylmethyl)phenyl]-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000032 mM
0.0016
3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid
-
i.e. 3-[1-(p-chlorobenzvl)-5-isopropyl-3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid or FLAP, formerly designated L-663,536, a lipoxygenase inhibitor, IC50: 0.0016 mM
0.00006
3-[3-(benzylsulfanyl)-1-(4-chlorobenzyl)-5-[4-[(4-chloro-2-fluorophenyl)ethynyl]phenyl]-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.0021
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.0024
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
pH and temperature not specified in the publication
0.01
3-[3-(tert-butylsulfanyl)-1-methyl-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.01 mM
0.0032
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-(3-phenylpropyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0032 mM
0.0067
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1-prop-2-en-1-yl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.0067 mM
0.01
3-[3-(tert-butylsulfanyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.01 mM
0.00026
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-4-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.00026
3-[3-[(tert-butylsulfanyl)acetyl]-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00026 mM
0.000006
3-[4-(2'-acetyl-2-fluorobiphenyl-4-yl)-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.000016
3-[4-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
-
0.01
3-[4-[3-(2,3-dimethylphenoxy)propoxy]phenyl]propanoic acid
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.00016
3-[5-biphenyl-3-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00016 mM
0.000016
3-[5-biphenyl-4-yl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.000016 mM
0.00033
3-[5-tert-butyl-1-(4-chlorobenzyl)-3-methyl-1H-indol-2-yl]-2,2-dimethylpropanoic acid
-
IC50: 0.00033 mM
0.03
4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-3-ol
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4'-[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-ol
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4'-[1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazol-4-yl]biphenyl-4-amine
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-(2'-[[2-chloro-5-(trifluoromethyl)phenoxy]methyl]biphenyl-4-yl)-1-[2-(2-methylphenyl)ethyl]-1H-1,2,3-triazole
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.00459
4-(4'-butyl-biphenyl-4-yl)-3-(4-butyl-phenyl)-5-hydroxy-5H-furan-2-one
Q9JM51
-
0.03
4-(4'-phenoxybiphenyl-4-yl)-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.00057
4-(4-benzylphenyl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
-
pH and temperature not specified in the publication
0.00039
4-(4-chlorobenzyl)-2,6-bis[4-(trifluoromethoxy)phenyl]-4H-thieno[3,2-b]pyrrole
-
-
0.00011
4-(biphenyl-4-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole
-
pH and temperature not specified in the publication
0.005
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzamide
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.005
4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzoic acid
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.03
4-[(4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1H-1,2,3-triazol-1-yl)sulfonyl]benzoic acid
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-[2'-[(naphthalen-1-yloxy)methyl]biphenyl-4-yl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-[4-(phenanthren-9-yl)phenyl]-1-(3-phenylpropyl)-1H-1,2,3-triazole
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
4-[4-benzyl-1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-5-yl]benzaldehyde
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.0032
4-[[4-(biphenyl-4-yl)-1H-1,2,3-triazol-1-yl]methyl]-3-nitrobenzoic acid
-
pH and temperature not specified in the publication
0.03
5-(4-bromophenyl)-3-(2-chloro-6-fluorophenyl)-1,2,4-oxadiazole
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.03
5-(dimethylamino)-N-[4'-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]biphenyl-4-yl]naphthalene-1-sulfonamide
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.00084
5-hydroxy-3-naphthalen-2-yl-4-(3-naphthalen-2-yl-phenyl)-5H-furan-2-one
Q9JM51
-
0.00094
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(1,3-thiazol-2-ylethynyl)pyridine
-
pH and temperature not specified in the publication
0.000013
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohex-1-en-1-ylethynyl)pyridine
-
pH and temperature not specified in the publication
0.000033
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclohexylethynyl)pyridine
-
pH and temperature not specified in the publication
0.00017
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(cyclopropylethynyl)pyridine
-
pH and temperature not specified in the publication
0.000023
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
pH and temperature not specified in the publication
0.00048
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(pyridin-3-ylethynyl)pyridine
-
pH and temperature not specified in the publication
0.0025
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-ethynylpyridine
-
pH and temperature not specified in the publication
0.000009
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(2-chlorophenyl)ethynyl]pyridine
-
pH and temperature not specified in the publication
0.000004
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(3-chlorophenyl)ethynyl]pyridine
-
pH and temperature not specified in the publication
0.000031
5-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-[(4-chlorophenyl)ethynyl]pyridine
-
pH and temperature not specified in the publication
0.00002
5-[2-(2-chloro-6-fluorophenyl)-5-methyl-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
pH and temperature not specified in the publication
0.000016
5-[5-(2-chloro-6-fluorophenyl)-1H-1,2,4-triazol-3-yl]-2-(phenylethynyl)pyridine
-
pH and temperature not specified in the publication
0.000001
5-[5-bromo-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
pH and temperature not specified in the publication
0.000005
5-[5-chloro-2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]-2-(phenylethynyl)pyridine
-
pH and temperature not specified in the publication
0.0067
6-nitro-3-(m-tolylamino) benzo[d]isothiazole 1,1-dioxide
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0236
6-nitro-N-phenyl-1,2-benzothiazol-3-amine 1,1-dioxide
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
6-nitro-N-[3-(propan-2-yl)phenyl]-1,2-benzothiazol-3-amine 1,1-dioxide
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0011
7-hydroxy-N,N'-bis(2,4,6-trimethylphenyl)naphthalene-1,3-disulfonamide
-
-
0.044
acetaminophen
-
-
0.005
aminomethyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0003
arachidonic acid
-
-
0.0018
benzothiophene gamma-hydroxybutenolide
Q9JM51
-
0.0000008
biarylimidazole
-
-
0.0012
cysteinyl leukotriene LTC4
-
-
0.0003
deoxy-prostaglandin J2
-
IC50: 0.0003 mM
0.23
dyphylline
-
-
0.0003
eicosapentaenoic acid
-
-
0.01
ethyl 2-([4-[3-(quinolin-6-yloxy)propoxy]phenyl]sulfanyl)hexanoate
-
IC50 above 0.01 mM, in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.0056
ethyl 2-[[4-chloro-6-(quinolin-6-ylamino)pyrimidin-2-yl]sulfanyl]nonanoate
-
-
0.0072
methyl 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(1-methylethyl)-1H-indol-2-yl]-2,2-dimethylpropanoate
-
IC50: 0.0072 mM
0.005
methyl 4-([4-[2-(2-chloro-6-fluorophenyl)-1H-imidazol-4-yl]phenyl]ethynyl)benzenesulfinate
-
IC50 above 0.005 mM, pH and temperature not specified in the publication
0.0000017
methyl 4-[6-bromo-2-(2-chloro-6-fluorophenyl)-1H-phenanthro[9,10-d]imidazol-9-yl]but-3-ynoate
-
-
0.000003
MF63
-
pH and temperature not specified in the publication
0.0016
MK-886
-
-
0.0024
MK-886
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.0032
MK-886
-
-
0.0024
MK886
-
in 0.1 M potassium phosphate buffer, pH 7.4, at 4C
0.05
N-(1,3-benzodioxol-4-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(2-methylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(3,4-dimethoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(3-bromobenzyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4Cn
0.0073
N-(3-bromophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0057
N-(3-chlorophenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0088
N-(3-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(3-tert-butylphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0169
N-(4-methoxyphenyl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(5-bromonaphthalen-1-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.00015
N-(6-nitro-1,1-dioxido-1,2-benzothiazol-3-yl)quinolin-5-amine
-
0.1 M potassium phosphate buffer, pH 7.4, 4C
0.05
N-(biphenyl-3-yl)-6-nitro-1,2-benzothiazol-3-amine 1,1-dioxide
-
above, 0.1 M potassium phosphate buffer, pH 7.4, 4C
0.0013
N-[4-chloro-3-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-2-(trifluoromethyl)benzamide
-
-
0.01 - 0.02
NS-398
-
COX-2 inhibitor, IC50: 0.01-0.02 mM
0.02
NS-398
-
-
0.11
Oxacillin
-
-
0.0000165
PF-9184
-
recombinant enzyme, in 100 mM K3PO4 buffer at pH 6.2
0.00108
PF-9184
-
in 100 mM K3PO4 buffer at pH 6.2
0.08
sulindac
-
-
0.08
sulindac sulfide
-
-
0.03
[1-[(phenylsulfanyl)methyl]-1H-1,2,3-triazol-4-yl]methyl benzoate
-
IC50 above 0.03 mM, pH and temperature not specified in the publication
0.0012
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl](phenyl)acetic acid
-
in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
0.01
[[4,6-bis(2-phenylethoxy)pyrimidin-2-yl]sulfanyl]acetic acid
-
IC50 above 0.01 mM, in potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione, at 4C
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
0.04
-
substrate 15-hydroperoxy-prostaglandin E2
0.043
-
substrate 5-hydroperoxyeicostetraenoic
0.054
-
mutant enzyme T131V/L135F/A138F, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.059
-
wild type enzyme, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.086
-
mutant enzyme V131T/F135L/F138A, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.17
-
substrate cumene hydroperoxide
0.214
-
wild type enzyme, in 0.1 M potassium phosphate buffer, pH 7.4, 2.5 mM glutathione, at 4C
0.81
-
substrate 1-chloro-2,4-dinitrobenzene
1.6
-
prostaglandin H1
1.8
-
prostaglandin H2
2
-
cPGES alone
2.2
-
cPGES plus casein kinase II
2.5
-
cPGES plus casein kinase II plus Hsp90
100 - 200
-
in the presence of 0.4 mM prostaglandin H2 or prostaglandin G2 and 2.5 mM glutatione
120
-
substrate (5Z,13E)-(15S)-9a,11a-epidioxy-15-hydroxyprosta-5,13-dienoate
190
-
substrate prostaglandin G2
510
-
in the presence of 10 microM prostaglandin H2 or prostaglandin G2 and 2.5 mM glutatione
additional information
-
-
additional information
-
measurement of urinary prostaglandin E2
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
5.5 - 7
-
-
6 - 7
-
GSH-dependent enzyme from deferent duct
6 - 8
-
GSH-independent enzyme from heart
6.2
-
IgG1(hei-26)-reactive protein
6.5 - 7.5
-
IgG1(hei-7)-reactive protein
6.5
-
enzyme assay
7 - 8
-
-
7.2
-
assay at
7.2
Q9N0A4
assay at
7.4
-
enzyme activity assay
7.4
-
microsomal membranes are incubated with PGH2, enzyme activity assay
8
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
5 - 10
-
pH 5: about 75% of maximal activity, pH 10: about 70% of maximal activity, GSH-dependent enzyme from deferent duct
5 - 12
-
pH 5: about 60% of maximal activity, pH 9: about 75% of maximal activity, pH 12: about 90% of maximal activity, GSH-independent enzyme from heart
5.5 - 9.5
-
almost inactive below pH 5.5 and above pH 9.5
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
4
-
microsomal membranes are incubated with PGH2, enzyme activity assay
4
Q9N0A4
assay at
20
-
activity assay at room temperature
22
-
assay at room temperature
25
-
assay at
additional information
-
microsomal suspension is incubated on ice with PGH2, enzyme activity assay
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
50
-
PGE synthase activity is completely lost at 50C for 5 min
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
low expression of mPEGS-2 in the urothelium
Manually annotated by BRENDA team
-
in brain mPGES-2 is detected in neurons, activated microglia, and endothelium, but not in resting microglia, astrocytes, or smooth muscle cells
Manually annotated by BRENDA team
-
in normal breast the enzyme is seen in myoepithelial cells and in stromal fibroblasts and vascular smooth muscle, in breast disease, the enzyme is observed in epithelial cells adjacent to cancer, in scattered foci of fibrocystic disease, in ductal carcinoma in situ and in invasive cancers, in addition to myoepithelial cells
Manually annotated by BRENDA team
-
colocalized with cyclooxygenase-2
Manually annotated by BRENDA team
-
weak enzyme expression
Manually annotated by BRENDA team
-
weak enzyme expression, in the tubular epithelial cells of the caput and cauda
Manually annotated by BRENDA team
-
osteoarthritic chondrocyte
Manually annotated by BRENDA team
Q2TJZ7
highest abundance of the protein
Manually annotated by BRENDA team
-
from women undergoing treatment for infertility, expression of mPGES-2, mPGES-1, and cPGES
Manually annotated by BRENDA team
-
extravillous cytotrophoblast is strongly posistive for enzyme protein in the basal plate
Manually annotated by BRENDA team
-
follicular dendritic cell
Manually annotated by BRENDA team
-
middle frontal gyrus tissue
Manually annotated by BRENDA team
Q2TJZ7
intermediate abundance of the protein
Manually annotated by BRENDA team
-
in the tubular epithelial cells of the caput and cauda
Manually annotated by BRENDA team
-
at least 2 different proteins with PGE-PGH isomerase activity, epithelium cells
Manually annotated by BRENDA team
-
epithelial cells of the basal layer, co-localization of isoform mPGES-1 and COX-2 after induction of oesophagitis
Manually annotated by BRENDA team
-
pulmonary epithelial cell
Manually annotated by BRENDA team
-
pEJ-ras transformed
Manually annotated by BRENDA team
-
colocalized with cyclooxygenase-2
Manually annotated by BRENDA team
-
gingival fibroblast
Manually annotated by BRENDA team
Q5DI74, Q6PWL5, Q9N0A4
low level of cPGES
Manually annotated by BRENDA team
Q5DI74, Q6PWL5, Q9N0A4
low level of mPGES-2
Manually annotated by BRENDA team
Q5DI74, Q6PWL5, Q9N0A4
mPGES-1
Manually annotated by BRENDA team
Q9JM51
both microsomal enzyme immunostaining and mRNA, enzyme is induced by equine and human chorionic gonadotropin treatment
Manually annotated by BRENDA team
-
faint expression levels
Manually annotated by BRENDA team
Q5IHX6, Q5IHX7
-
Manually annotated by BRENDA team
Q5IHX6, Q5IHX7
-
Manually annotated by BRENDA team
-
highest activity of nongenital organs
Manually annotated by BRENDA team
Q2TJZ7
intermediate abundance of the protein
Manually annotated by BRENDA team
-
mainly inner medulla, expression overview
Manually annotated by BRENDA team
Q2TJZ7
intermediate abundance of the protein
Manually annotated by BRENDA team
-
lowest protein expression
Manually annotated by BRENDA team
-
mesenchymal cells of the basal layer, co-localization of isoform mPGES-1 and COX-2 after induction of oesophagitis
Manually annotated by BRENDA team
-
mPGES-2 colocalizedswith microglia in activated (amoeboid-shaped) cells
Manually annotated by BRENDA team
-
faint expression levels
Manually annotated by BRENDA team
-
expressed to a lesser extent
Manually annotated by BRENDA team
Q2TJZ7
intermediate abundance of the protein
Manually annotated by BRENDA team
-
isoform mPGES-1 localizes mostly in myometrial and vascular smooth muscle cells of pregnant women. Isoform cPGES is diffusely located throughout the myometrium. Expression of COX-2 and isoform mPGES-1 mRNA with term labour, whereas cPGES expression does not change. Interleukin 1beta stimulates release of prostaglandin E2 by myometrical smooth muscle cells and increases COX-2 and mPGES-1 mRNA and protein expression, isoform mPGES-2 protein is largely in stromal cells surrounding smooth vascular muscle. Expression of mPGES-2 mRNA increases with term labour and preterm labour
Manually annotated by BRENDA team
-
myometrial smooth muscle cell
Manually annotated by BRENDA team
-
only isoform mPGES-1 can be found in neutrophils, it co-localizes with COX-2 and its expression is mainly constitutive
Manually annotated by BRENDA team
Q9JM51
exclusive localization of cytosolic enzyme, no obvious effect of treatment with equine chorionic gonadotropin on mRNA or protein level
Manually annotated by BRENDA team
-
epithelium, mPEGS-2
Manually annotated by BRENDA team
Q95L14
prostaglandin E synthases are mostly concentrated in the oviductal epithelial layer and primarily expressed in the ampulla section of the oviduct and to a lesser extent in the isthmus and the isthmic-ampullary junction, prostaglandin E synthases are mostly concentrated in the oviductal epithelial layer and primarily expressed in the ampulla section of the oviduct and to a lesser extent in the isthmus and the isthmic-ampullary junction, the mPGES-1 protein is highly expressed in the contralateral oviduct, prostaglandin E synthases are mostly concentrated in the oviductal epithelial layer and primarily expressed in the ampulla section of the oviduct and to a lesser extent in the isthmus and the isthmic-ampullary junction, the mPGES-2 is mostly expressed in the ipsilateral oviduct
Manually annotated by BRENDA team
Q5DI74, Q6PWL5, Q9N0A4
expression of the primary form of PGES, mPGES-1
Manually annotated by BRENDA team
Q5IHX6, Q5IHX7
at 24 h after fertilization, endothelial cells of the pharyngeal arch vasculature
Manually annotated by BRENDA team
-
immunolocalized in extravillous trophoblasts and macrophages, in early gestation also in cytotrophoblasts and syncytiotrophoblasts, immunolocalized to the fibroblasts and macrophages in villous stroma, also in apoptotic early gestational syncytiotrophoblasts
Manually annotated by BRENDA team
-
application of glucocorticoids to mother or fetus significantly stimulate enzyme isoform mPGES1 in placenta. Enzyme is localized to placental trophoblast cells
Manually annotated by BRENDA team
Q5IHX6, Q5IHX7
-
Manually annotated by BRENDA team
-
barely detectable
Manually annotated by BRENDA team
-
pulmonary epithelial cell
Manually annotated by BRENDA team
-
high expression of mPEGS-2
Manually annotated by BRENDA team
-
moderate enzyme expression
Manually annotated by BRENDA team
-
almost undetectable
Manually annotated by BRENDA team
-
lowest protein expression
Manually annotated by BRENDA team
-
normal and psoriatic
Manually annotated by BRENDA team
-
expressed to a lesser extent, faint expression levels
Manually annotated by BRENDA team
-
enzyme protein is prominent in vesicles separating from syncytiotrophoblast into the intervillous space
Manually annotated by BRENDA team
-
expressed to a lesser extent
Manually annotated by BRENDA team
-
spermatogonia, Sertoli cells and primary spermatocytes
Manually annotated by BRENDA team
-
weak enzyme expression, Leydig cells, Sertoli cells, seminiferous tubules
Manually annotated by BRENDA team
Q5DI74, Q6PWL5, Q9N0A4
mPGES-1
Manually annotated by BRENDA team
-
placental trophoblast
Manually annotated by BRENDA team
-
constitutive expression of enzyme is associated with increased prostaglandin E2 production and stimulation of growth. Inhibition of enzyme activity and expression block the release of prostaglandin E2 and decrease cellular proliferation. Antiproliferative effects may be overcome by exogenous prostaglandin E2
Manually annotated by BRENDA team
-
low expression of mPEGS-2
Manually annotated by BRENDA team
-
expression of cPEGS, mPEGS-2, and mPEGS-1
Manually annotated by BRENDA team
-
enzyme protein is elevated in the endometrium during spontaneous term labour and after estradiol treatment. Enzyme is localized to endometrial stromal cells
Manually annotated by BRENDA team
-
epithelial cells, low expression of mPEGS-2
Manually annotated by BRENDA team
-
intrauterine tissue of pregnant ewe
Manually annotated by BRENDA team
-
and other genital accessory organs
Manually annotated by BRENDA team
-
in the epithelium from the proximal segment to the distal portion of the vas deferens and ampulla
Manually annotated by BRENDA team
-
strong enzyme expression, in the epithelium from the proximal segment to the distal portion of the vas deferens and ampulla
Manually annotated by BRENDA team
-
weak enzyme expression
Manually annotated by BRENDA team
-
cells express both microsomal isoforms mPGES-1 and mPGES-2 and cytosolic isoform cPGES, cells express both microsomal isoforms mPGES-1 and mPGES-2 and cytosolic isoform cPGES. Isoform mPGES-1 contributes most to total activity and is induced by interleukin IL-1beta, which in turn reduces the ability of cells to produce prostaglandin I2
Manually annotated by BRENDA team
-
peripheral blood monocyte, no basal expression of enzyme, but strong induction of expression by proinflammatory stimulation via LPS. In alternatively activated M2 monocytes-macrophages, interleukins IL-4, IL-13, and to a lesser extent, IL-10 or interferon IFN-gamma inhibit LPS-induced expression of enzyme. Induction of enzyme expression correlates with changes at the protein level and production of prostaglandin E2
Manually annotated by BRENDA team
additional information
-
DU4475 cell, highest protein expression
Manually annotated by BRENDA team
additional information
-
endometrium, located in epithelial, glandular and stromal cells
Manually annotated by BRENDA team
additional information
Q2TJZ7
endometrium, mainly in luminal and glandular epithelium, higher levels of PGES-1 mRNA occur during pregnancy on days 10-11 when compared with days 12-17, intermediate levels of PGES-1 protein are observed on days 10-13, afterwards, PGES-1 mRNA and protein expression decrease, followed by an increase from days 18-19 or 22-23 of pregnancy, highest mRNA and protein levels are reached on days 24-25
Manually annotated by BRENDA team
additional information
-
Hs 578T cell
Manually annotated by BRENDA team
additional information
-
in patients with rheumatoid arthritis, the protein is overexpressed in synovial tissue, particularly by macrophages and fibroblasts in the synovial lining layer
Manually annotated by BRENDA team
additional information
Q6BCL2
protein expression occurs in luminal epithelial and stromal cells around the implanting blastocyst on day 5 of pregnancy, with the progression of implantation to day 6, the protein is mainly expressed in the cells of the primary decidual zone
Manually annotated by BRENDA team
additional information
-
seminal vesicular gland
Manually annotated by BRENDA team
additional information
-
ZR-75-1 cell
Manually annotated by BRENDA team
additional information
-
distribution of mPEGS-2, overview
Manually annotated by BRENDA team
additional information
-
the enzyme expression is altered in rats with nephrogenic and central diabetes insipidus, expression overview
Manually annotated by BRENDA team
additional information
-
tissue distribution of isozme expression, overview
Manually annotated by BRENDA team
additional information
Q5DI74, Q6PWL5, Q9N0A4
tissue distribution of isozyme expression, overview
Manually annotated by BRENDA team
additional information
-
tissue-specific expression analysis
Manually annotated by BRENDA team
additional information
Q9JM51
no microsomal enzyme immunostaining or mRNA in thecal cell or oocyte
Manually annotated by BRENDA team
additional information
-
MPGES-1 is not detected in LNCaP cells
Manually annotated by BRENDA team
additional information
Q9N0A4
abundant tissue distribution of isozyme mPGES2
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
Q5IHX6, Q5IHX7
-
Manually annotated by BRENDA team
Q5DI74, Q6PWL5, Q9N0A4
-
Manually annotated by BRENDA team
-
associated, mPEGS-1 and mPEGS-2
Manually annotated by BRENDA team
Q9N0A4
membrane-associated prostaglandin E synthase-2
Manually annotated by BRENDA team
Q5IHX6, Q5IHX7
-
-
Manually annotated by BRENDA team
-
at least 2 different proteins with PGE-PGH isomerase activity
-
Manually annotated by BRENDA team
-
Golgi membrane-associated
-
Manually annotated by BRENDA team
-
isozyme mPGES-1
-
Manually annotated by BRENDA team
O14684
microsomal isozyme PGE2 synthase-1
-
Manually annotated by BRENDA team
additional information
-
cPGES is directly associated with and phosphorylated by casein kinase 2, cPGES, casein kinase 2 and Hsp90 form a stoichiometric complex of 1:1:1 immediately after cell activation, Hsp90 acts as an essential scaffold protein that brings cPGES and casein kinase 2 in proximity, thereby allowing their efficient functional interaction under physiological condition
-
Manually annotated by BRENDA team
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
16000
-
SDS-PAGE
660677
16000
-
SDS-PAGE
661310
16000
-
determined by SDS-PAGE and Western Blot analysis
692088
16000
-
determined by SDS-PAGE and Western Blot analysis
693452
17000
-
SDS-PAGE
663277
17000
-
monomer, determined by SDS-PAGE and Western blot analysis
690622
17300
Q2TJZ7
calculated from amino acid sequence
661605
18000
-
determined by SDS-PAGE and Western Blot analysis
693240
18000
-
monomer
693372
18800
-
determined by SDS-PAGE and Western Blot analysis
691476
19000
-
calculated, His-tagged mPGES-1
691476
23000
-
SDS-PAGE
661310
32000
-
SDS-PAGE
661310
33000
-
SDS-PAGE
660677
33000
-
dimer, determined by SDS-PAGE and Western blot analysis, crosslinked subunits
690622
45000
-
trimer, determined by SDS-PAGE and Western blot analysis, crosslinked subunits
690622
57000
-
trimer, determined by SDS-PAGE and Western Blot analysis
691476
215000
-
gradient centrifugation, density equilibrium centrifugation, gel filtration
662768
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
?
-
x * 17000, SDS-PAGE
?
-
x * 17500, IgG1(hei-7)-reactive protein, SDS-PAGE, x * 180000, IgG1(hei-26)-reactive protein, SDS-PAGE
?
-
8 different subunits detected by SDS-PAGE, activity resides mainly in subunit H, MW 25700
?
-
x * 17500, SDS-PAGE
dimer
-
crystal structure
dimer
Q9N0A4
crystal structure
oligomer
-
-
trimer
-
crystal structure
trimer
-
3 * ?, gradient centrifugation, density equilibrium centrifugation, gel filtration
trimer
-
trimeric state characterized by chemical cross-linking with glutaraldehyde
homotrimer
-
-
additional information
Q9N0A4
structure-function analysis, overview
additional information
-
the N-terminal domain contains the GSH-binding site (G-site), and the C-terminal domain contains the binding site for hydrophobic substrate and PGH2
Crystallization/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
purified enzyme in complex with glutathione sulfonic acid, sitting drop vapor diffusion method, mixing of 10 mg/ml protein in 20 mM Tris-HCl , pH 8.5, and 0.2 M NaCl with 0.1 M HEPES, pH 7.5, 30% PEG 400 w/v, and 20% 1,2-propanediol v/v, in a 1:1 or 1:2 ratio, X-ray diffraction structure determination and analysis at 1.37 A resolution, molecular replacement
-
purified recombinant microsomal isozyme PGE2 synthase-1, in presence of beta-octyl-glycoside and GSH or 1-(4-phenylphenyl)-2-(S-glutathionyl)-ethanone (bis-phenyl-GSH), hanging drop vapor diffusion method, the reservoir solutions used contain 100 mM CAPSO, pH 9.5, 30% PEG 400, 100 mM NaCl, and 100 mM Li2SO4 (mersalyl acid soak and bis-phenyl-GSH complex) or 100 mM Tris, pH 8.0-8.5, 30% PEG400, 100 mM NaCl, and 1 mM TCEP (native GSH complex), 4C, X-ray diffraction structure determination and analysis at 1.2 A resolution
O14684
red-coloured protein purified after growth of Escherichia coli in LB medium containing delta-aminolevulinate and Fe(NO3)3. Enzyme contains bound glutathione and heme
-
the structure of human MPGES1 is determined in complex with the tripeptide gamma-L-glutamyl-L-cysteinyl-glycine, glutathione, at 3.5 A in-plane resolution using electron crystallography
-
three-dimensional model of substrate-domain and its binding with subsrtates prostaglandin H2 and glutathione. Residue Y130 plays a key role in binding with prostaglandin H2 and in the catalytic process. R110 and T114 interact intensively with the carbonyl tail of prostaglandin H2, whereas Q36 and Q134 only enhance the prostaglandin H2 binding affinity. Prostaglandin H2 interacts with glutathione through hydrogen binding between the peroxy group of prostaglandin H2 and the -SH group of glutathione
-
threedimensional structural model of binding with inhibitors, quantitative structure-activity correlation
-
purified recombinant His-tagged truncated mPGES-2, complexed with anti-inflammatory drug IMN, 10 mg/ml protein in 1.7 M ammonium sulfate, 0.1 M sodium acetate-HCl, pH 5.5, and 1.5 mM indomethacin, sitting drop vapour diffusion method, 3 days, 22C, X-ray diffraction structure determinationand analysis at 2.6 A resolution, modeling; with an anti-inflammatory drug indomethacin, 2.6 A resolution
Q9N0A4
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
7 - 8
-
pH-range of highest stability, 35C, 7.5 min, either in presence or absence of glutathione
3129
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
0
-
half-life: 20 h
3128
25
-
pH 8.0, 0.1 M potassium phosphate buffer, half-life: 30 min
3129
additional information
-
thiol compounds, glutathione, dithiothreitol, 2-mercaptoethanol or cysteine markedly protect from thermal inactivation
3129
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
thiol compounds, glutathione, dithiothreitol, 2-mercaptoethanol or Cys markedly protect from thermal inactivation
-
activity in solubilized membranes remains stable for a prolonged time in the presence of reduced glutathione and glycerol
-
resistant to freeze-thawing
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-20C, 1 mM glutathione, pH 7.0, completely inactivated after a few weeks
-
-70C, 1 mM glutathione, pH 7.0, stable for at least several months
-
-20C, 6 months, no loss of activity
-
4C, solubilized membranes, 10 d, 50% loss of activity
-
4C, solubilized membranes, 24 h, 30% loss of activity
-
-80C, stable
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
recombinant enzyme by ammonium sulfate fractionation, ion exchange chromatography, and gel filtration
-
detergent, hydroxyapatite column
-
microsomal membranes are prepared
-
microsomes are prepared
-
purification after expression of N-terminally truncated enzyme in recombinant Escherichia coli growing in LB medium containing delta-aminolevulinate and Fe(NO3)3 gives a protein of red colour. Purification after growth of Escherichia coli on minimal medium gives a colourless protein
-
recombinant active isozyme mPGES-1 from Spodoptera frugiperda Sf9 cell microsomes by hydroxylapatite chromatography
O14684
recombinant His-tagged mPGES-1, hydroxyapatite, Ni2+-affinity chromatography
-
using a Ni-NTA and a Mono Q-Sepharose column
-
using Ni-NTA affinity and size exclusion chromatography
-
; recombinant His-tagged truncated mPGES-2 from Escherichia coli strain BL21 by nickel affinity chromatography
Q9N0A4
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
recombinant expression
-
;
Q5IHX6, Q5IHX7
expressed in 293-F cells
-
expressed in Escherichia coli BL21(DE3) cells
-
expressed in Escherichia coli BL21Star (DE) pLysS cells
-
expression analysis
-
expression in Escherichia coli
-
expression in Escherichia coli cells
-
expression in Sf9 insect cells
-
expression of histidine-tagged mPGES-1 in Escherichia coli
-
expression of N-terminally truncated enzyme in Escherichia coli
-
from human placenta cDNA library, expression in Escherichia coli
-
into the TA vector and subsequently into pET-28a for expression in various Escherichia coli strains, the expression rate is enhanced by modifying the utility of specific codons
-
into the vector pET30 for expression in Escherichia coli BL21Star DE3 cells
-
into the vector pPICZA for overexpression in Pichia pastoris cells
-
isozyme mPGES-1, recombinant functional expression in Spodoptera frugiperda Sf9 cells using the baculovirus transfection method
O14684
cPGES, expression analysis; mPGES-1, expression analysis; mPGES-2, expression analysis
Q5DI74, Q6PWL5, Q9N0A4
expression in Escherichia coli; overexpression of truncated mPGES-2, comprising residues 1-87, with an extended His-tag in Escherichia coli strain BL21 by nickel affinity chromatography
Q9N0A4
determination of genomic structure of mPEGS-2
-
expressed in Escherichia coli BL21Star (DE) pLysS cells
-
expression in Escherichia coli
-
-
Q2TJZ7
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
0.01 mM cobalt protoporphyrin IX down-regulates mPGES-1 protein
-
interleukin-1beta does not change expression of MPGES-1 in the prostate cancer cell lines
-
100 units/ml interleukin-1beta induces the expression of COX-2 and mPGES-1 in osteoarthritic chondrocytes
-
mPGES-2 immunoreactivity is particularly elevated in the pyramidal neurons of brains from three of five sporadic and four of five familial Alzheimer's disease patients compared with four of five age-matched control brains that showed minimal immunoreactivity
-
interleukin-1beta (1 ng/ml) induces mPGES-1 expression
-
iron does not induce the enzyme expression
Q9N0A4
inhibition of NADPH-oxidase negatively modulates mPGES-1 expression induced by tobacco smoke/interleukin-1beta. The activation of mPGES-1 is negatively regulated by prostaglandin I2
-
1 mM glutamate up-regulates the expression of mPGES-1 to about 3fold that in the controls
-
microinjection of kainic acid induces mPGES-1 in venous endothelial cells but not in neurons or astrocytes
-
the expression of mPGES-1 in wild type mice is markedly upregulated in the gastric ulcer tissues compared with normal gastric tissues without ulcers
-
tobacco smoke (EC50 about 5 puffs/l) interacting with IL-1beta (0.002 mg/l) upregulates PGE2 production and mPGES-1 expression, reaching a plateau at 4-6 h
-
1 mM glutamate up-regulates the expression of mPGES-1 to about 3fold that in the controls
-
microinjection of kainic acid induces mPGES-1 in venous endothelial cells but not in neurons or astrocytes
-
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
D97A
-
site-directed mutagenesis, isomerase inactive mutant
N96A
-
site-directed mutagenesis, the mutant shows reduced isomerase activity compared to the wild-type enzyme
R99A
-
site-directed mutagenesis, isomerase inactive mutant
E66A
-
mutant, fraction of wild-type activity, 53%
E77A
-
mutant, no activity
H72A
-
mutant, fraction of wild-type activity, 32%
N74A
-
the mutant shows increased Km compared to the wild type enzyme
Q134E
-
fivefold increase in Km value
Q36E
-
tenfold increase in Km value
R110A
-
mutant, no activity
R110S
-
mutant, no activity
R110T
-
18% of wild-type activity
R122A
-
the mutant shows increased Km compared to the wild type enzyme
R126A
-
mutant, exhibits a glutathione-dependent reductase activity, which allows conversion of prostaglandin H2 into prostaglandin F2alpha
R126A
-
the mutation of the enzyme abolishes its PGES activity to exhibit a novel glutathione-dependent reductase activity
R126Q
-
mutant, exhibits a glutathione-dependent reductase activity, which allows conversion of prostaglandin H2 into prostaglandin F2alpha
R126Q
-
the mutation of the enzyme abolishes its PGES activity to exhibit a novel glutathione-dependent reductase activity
R67A
-
mutant, no activity
R70A
-
mutant, fraction of wild-type activity, 58%
R70A
-
the mutant shows increased Km compared to the wild type enzyme
R70A/R122A
-
the mutant shows increased Km compared to the wild type enzyme, the double mutant of the mPGES-1 significantly reduces the binding affinity of GSH
R70A/Y117A
-
mutant, fraction of wild-type activity, 7%
R70S
-
mutant, full activity
T114V
-
21% of wild-type activity
T129V
-
the mutant shows increased Km compared to the wild type enzyme
T131V/L135F/A138F
-
the mutant shows bout 4fold reduced specific activity towards prostaglandin H2 compared to the wild type enzyme and is not inhibited by 1-C-(2-chlorobenzene)-3-N-(naphthalen-1-yl)benzene-1,3-dicarboxamide
Y117A
-
mutant, fraction of wild-type activity, 1%
Y117A
-
the mutant shows increased Km compared to the wild type enzyme
Y117F
-
mutant, full activity
Y117F
-
the mutant still maintains full catalytic activity relative to the wild type
Y117S
-
the mutant shows increased Km compared to the wild type enzyme
Y130I
-
loss of most of the enzymic activity
A151G
-
shows similar activity as the wild-type
C-delta-35
-
35-amino acid COOH-terminal deletion, diminishes association of the enzyme with membranes
C58K
-
diminishes association of the enzyme with membranes
S113A
-
fails to be activated by casein kinase II
S118A
-
fails to be activated by casein kinase II
V131T/F135L/F138A
-
the mutant shows bout 4fold increased specific activity towards prostaglandin H2 compared to the wild type enzyme and is inhibited by 1-C-(2-chlorobenzene)-3-N-(naphthalen-1-yl)benzene-1,3-dicarboxamide
Y14F
-
shows similar activity as the wild-type
C-delta-35
-
35-amino acid COOH-terminal deletion, diminishes association of the enzyme with membranes
C58K
-
diminishes association of the enzyme with membranes
H72A
-
the mutation markedly decreases the mPGES-1 activity (32%)
additional information
-
knockdown of isoform mPGES-1 by siRNA results in downregulation of cytokine-induced mPGES-1 protein expression and activity. siRNA does not affect the cytokine-stimulated production of prostaglandin E2, whereas prostaglandin F2alpha levels are enhanced. Neither isoform mPGES-2 nor cPGES expression are affected by siRNA silencing of mPGES-1
Y130I
-
mutant, fraction of wild-type activity, 15%
additional information
-
in enzyme knock-out mice, the infarction, edema, apoptotic cell death, and caspase-3 activation in the cortex ischemia cell are all reduced. the behavioral neurological dysfunctions observed after ischemia in wild-type animals are significantly ameliorated in knock-out animals
additional information
-
in mice with targeted disruption of isoform mPGES-1 gene, basal excretion of prostaglandin E2 in urine is decreased by 50%. In female enzyme-deficient mice, there is a reciprocal increase in basal excretion of other prostanoids. Urinary osmolalities are similar in wild-type and enzyme deficient animals at baseline and after 12 h of water deprivation, and there are no differences in blood pressure on control or high- or low-salt diet. Furesemide-associated diuresis is reduced in male enzyme-deficient animals
additional information
-
isoform mPGES-1 knockout mice. Contrary to wild-type, in knock-out animals no prostaglandin E2 production is found in osteoblast after administration of LPS. While in wild-type, LPS reduces the bone volume in femur associated with an increased number of osteoclasts, this loss is reduced in knock-out mice. LPS induces the loss of alveolar bone in wild-type, but not in the mutants
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
medicine
Q5IHX6, Q5IHX7
antiinflammatory drug target, deletion of microsomal mPGES-1 abrogates inflammation
drug development
-
the enzyme constitues an attractive drug target for treatment of inflammatory diseases
drug development
-
the enzyme is a potential target for therapy of breast cancer
medicine
-
a considerable increase of mPGES-2 expression is observed in human colorectal cancer
medicine
-
17beta-estradiol and proinflammatory cytokines can act together to up-regulate PTGES, the finding supports a model whereby estrogens and inflammatory factors orchestrate a complex network of cross talk and feedback mechanisms that can contribute to hormone-dependent breast tumor growth and progression
medicine
-
licofelone suppresses inflammatory PGE2 formation preferentially by inhibiting mPGES-1 at concentrations that do not affect COX-2
medicine
-
mPGES-1 expression is significantly elevated in Alzheimer's disease tissue
medicine
-
mPGES-1 is a potential target for inhibitors, pathological conditions, such as inflammation, pain, fever, anorexia, atherosclerosis, stroke, and tumorigenesis are related to elevated levels of PGE2
medicine
-
mPGES-1 is a promising target for the development of anti-inflammatory drugs
medicine
-
mPGES-1 plays a role in atherosclerosis, stroke, inflammation, pain and fever
medicine
-
MPGES1 has been implicated in a number of human diseases or pathological conditions, such as rheumatoid arthritis, fever, and pain, and is therefore regarded as a primary target for development of novel antiinflammatory drugs
medicine
-
the selective inhibition of mPGES-1 generates anti-inflammatory effects without unwanted side effects involving homeostasis
medicine
-
MPGES-1 is an alternative therapeutic target in cancer cells expressing this enzyme
medicine
-
in enzyme knock-out mice, the infarction, edema, apoptotic cell death, and caspase-3 activation in the cortex ischemia cell are all reduced. the behavioral neurological dysfunctions observed after ischemia in wild-type animals are significantly ameliorated in knock-out animals. Microsomal enzyme mPGES-1 may be a critical determinant of postischemic neurological dysfunctions and a therapeutic target for treatment of stroke
medicine
-
use of isoform mPGES-1 as a target for the treatment of inflammatory bone disease
medicine
-
induction of various inflammatory cytokines in addition to overexpression of COX-2 and mPGES-1 could be risk factors of gastric carcinogenesis and may serve as a better gastric carcinogenesis model
medicine
-
mPGES-1 could be a potential therapeutic target of novel inhibitors for treatment of inflammatory diseases
medicine
-
mPGES-1 inhibitors have therapeutic potential in syndromes of cardiovascular inflammation, cancer and perhaps neurodegenerative disease
medicine
-
mPGES-1 is a potential target of anti-inflammatory drugs
medicine
-
inhibition of mPGES-1 may have clinical utility in the management of bone cancer pain
medicine
-
mPGES-1 is a therapeutic target for endometriosis
drug development
-
the enzyme represents a novel target for anti-inflammatory and anti-cancer drugs
medicine
-
mPGES-1 is involved in various types of pathology including inflammation, pain hyperalgesia, fever, and cancer
medicine
-
prostaglandin E2 derived from COX-2 and isoform mPGES-1 plays a significant role in the pathogenesis of chronic acid reflux oesophagitis, and possibly in basal hyperplasia and persistent inflammatory cell infiltration